Today The Q4 2016 EPS Estimates for Novartis AG Decreased by Leerink Swann (NVS)

Today The Q4 2016 EPS Estimates for Novartis AG Decreased by Leerink Swann (NVS)

Novartis AG (NYSE:NVS) – Research analysts at Leerink Swann lowered their Q4 2016 EPS estimates for shares of Novartis AG in a report released on Monday. Leerink Swann analyst S. Fernandez now anticipates that the brokerage will post earnings of $1.10 per share for the quarter, down from their previous forecast of $1.11. Leerink Swann also issued estimates for Novartis AG’s Q1 2017 earnings at $1.14 EPS, Q2 2017 earnings at $1.20 EPS, Q3 2017 earnings at $1.22 EPS, Q4 2017 earnings at $1.24 EPS, FY2017 earnings at $4.79 EPS, FY2018 earnings at $5.36 EPS, FY2019 earnings at $5.63 EPS, FY2020 earnings at $5.72 EPS and FY2021 earnings at $6.17 EPS.

A number of other research firms have also weighed in on NVS. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of Novartis AG in a research report on Thursday, January 19th. Jefferies Group LLC reaffirmed a “buy” rating on shares of Novartis AG in a research report on Sunday, October 16th. TheStreet lowered Novartis AG from a “buy” rating to a “hold” rating in a research report on Wednesday, September 28th. Credit Suisse Group lowered Novartis AG from an “outperform” rating to a “neutral” rating in a research report on Wednesday, January 11th. Finally, Berenberg Bank lowered Novartis AG from a “buy” rating to a “hold” rating in a research report on Tuesday, January 17th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating and three have issued a buy rating to the company’s stock. Novartis AG currently has an average rating of “Hold” and a consensus price target of $85.18.

Novartis AG (NYSE:NVS) traded up 2.6273% on Wednesday, reaching $71.8699. The company’s stock had a trading volume of 4,072,761 shares. The company’s 50 day moving average price is $71.56 and its 200-day moving average price is $76.20. Novartis AG has a 12-month low of $66.93 and a 12-month high of $83.58. The stock has a market cap of $170.73 billion, a PE ratio of 25.3420 and a beta of 0.68.

Novartis AG (NYSE:NVS) last posted its quarterly earnings data on Wednesday, January 25th. The company reported $1.12 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $1.12. Novartis AG had a return on equity of 15.25% and a net margin of 13.98%. The business had revenue of $12.32 billion for the quarter, compared to analysts’ expectations of $12.34 billion. During the same quarter in the previous year, the firm earned $1.14 earnings per share. The business’s revenue was down 1.6% on a year-over-year basis.

Several hedge funds have recently bought and sold shares of NVS. The Manufacturers Life Insurance Company purchased a new position in Novartis AG during the third quarter worth about $304,776,000. CGOV Asset Management purchased a new position in Novartis AG during the third quarter worth about $82,650,000. Parnassus Investments CA increased its position in Novartis AG by 22.9% in the third quarter. Parnassus Investments CA now owns 4,278,005 shares of the company’s stock worth $337,791,000 after buying an additional 796,109 shares during the period. Aristotle Capital Management LLC increased its position in Novartis AG by 31.9% in the second quarter. Aristotle Capital Management LLC now owns 2,736,946 shares of the company’s stock worth $225,825,000 after buying an additional 662,285 shares during the period. Finally, FMR LLC increased its position in Novartis AG by 65.6% in the second quarter. FMR LLC now owns 1,208,384 shares of the company’s stock worth $99,704,000 after buying an additional 478,679 shares during the period. 9.84% of the stock is owned by institutional investors and hedge funds.

About Novartis AG

Novartis AG is a holding company. The Company specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. Its portfolio includes medicines, eye care and generic pharmaceuticals. The Company’s segments include Pharmaceuticals, Alcon and Sandoz.

Related posts

Leave a Comment